Aliases & Classifications for Urticaria

MalaCards integrated aliases for Urticaria:

Name: Urticaria 12 29 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1555
ICD9CM 35 708.8
ICD10 33 L50 L50.2 L50.9
UMLS 69 C0029839

Summaries for Urticaria

Disease Ontology : 12 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary : Urticaria is related to asthma and angioedema, and has symptoms including abdominal pain, chest pain and constipation. An important gene associated with Urticaria is F12 (Coagulation Factor XII), and among its related pathways/superpathways are NF-kappaB Signaling and Development VEGF signaling via VEGFR2 - generic cascades. The drugs Clarinex and Cetirizine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and thyroid, and related phenotypes are hematopoietic system and immune system

Related Diseases for Urticaria

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
id Related Disease Score Top Affiliating Genes
1 asthma 28.5 FCER1A HNMT HRH1 LTC4S RNASE3 SELE
2 angioedema 23.3 ADGRE2 AOC1 C1S CMA1 CPN1 F12
3 vibratory urticaria 12.4
4 cholinergic urticaria 12.3
5 cold urticaria 12.2
6 aquagenic urticaria 12.2
7 solar urticaria 12.2
8 urticaria pigmentosa 12.2
9 physical urticaria 12.2
10 allergic urticaria 12.0
11 papular urticaria 11.9
12 schnitzler syndrome 11.9
13 nodular urticaria pigmentosa 11.8
14 muckle-wells syndrome 11.7
15 familial cold autoinflammatory syndrome 3 11.7
16 plaque-form urticaria pigmentosa 11.7
17 typical urticaria pigmentosa 11.7
18 dermatographia 11.6
19 familial cold-induced inflammatory syndrome 1 11.6
20 maculopapular cutaneous mastocytosis 11.3
21 familial cold autoinflammatory syndrome 11.3
22 familial cold autoinflammatory syndrome 4 11.0
23 mast cell disease 11.0
24 exercise-induced anaphylaxis 11.0
25 cutaneous mastocytosis 11.0
26 cryopyrin-associated periodic syndrome 11.0
27 peanut allergy 11.0
28 wheat allergy 11.0
29 familial dermographism 10.7
30 arthus reaction 10.7
31 episodic angioedema with eosinophilia 10.7
32 netherton syndrome 10.7
33 fascioliasis 10.7
34 hypersensitivity vasculitis 10.7
35 cystic echinococcosis 10.7
36 hypocomplementemic urticarial vasculitis 10.7
37 carboxypeptidase n deficiency 10.7
38 paragonimiasis 10.7
39 anca-associated vasculitis 10.7
40 monoclonal mast cell activation syndrome 10.7
41 atrial fibrillation 10.6 ADGRE2 FCER1A
42 anterior dislocation of lens 10.5 CMA1 RNASE3
43 multiple sclerosis 5 10.4 NLRP3 TPT1
44 brain ependymoma 10.4 PTGS1 PTGS2
45 ovarian remnant syndrome 10.4 PTGS1 PTGS2
46 corneal intraepithelial neoplasm 10.4 HRH1 NLRP3 RNASE3
47 marginal corneal ulcer 10.3 NLRP3 SELE
48 collagenous gastritis 10.2 CMA1 NLRP3 PLCG2 RNASE3
49 erythema multiforme 10.2
50 dermatitis 10.1

Comorbidity relations with Urticaria via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Ischemic Heart Disease

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to Urticaria

Symptoms & Phenotypes for Urticaria

UMLS symptoms related to Urticaria:


abdominal pain, chest pain, constipation, coughing, diarrhea, dyspepsia, edema, exanthema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, welts, vertigo/dizziness, gastrointestinal gas, symptoms

MGI Mouse Phenotypes related to Urticaria:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 AOC1 CMA1 FCER1A FCER2 HRH1 NLRP3
2 immune system MP:0005387 9.36 SELE CMA1 CPN1 FCER1A FCER2 HRH1

Drugs & Therapeutics for Urticaria

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Clarinex 17 DESLORATADINE Schering-Plough February 2002

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1 83881-51-0 2678
2
Desloratadine Approved, Investigational Phase 4,Phase 3,Phase 2 100643-71-8 124087
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
4
Levocetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1 130018-77-8
5
Omalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 242138-07-4
6
Hydroxyzine Approved Phase 4 68-88-2 3658
7
Loratadine Approved Phase 4,Phase 3,Phase 2 79794-75-5 3957
8
Fexofenadine Approved Phase 4,Phase 2 83799-24-0 3348
9
Cefazolin Approved Phase 4 25953-19-9 656510 33255
10
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
11
Clevidipine Approved Phase 4 167221-71-8
12
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
13
Azelastine Approved Phase 4,Phase 3 58581-89-8 2267
14
Icatibant Approved Phase 4,Phase 3,Phase 2,Phase 1 138614-30-9, 130308-48-4 71364
15
Dapsone Approved, Investigational Phase 4 80-08-0 2955
16
Menthol Approved Phase 4 2216-51-5 16666
17
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
18
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 1406-16-2
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
21
Bradykinin Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-82-2 439201
22 Ebastine Investigational Phase 4 90729-43-4
23
Lactitol Investigational Phase 4,Phase 2 585-86-4 3871
24 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Cholinergic Agents Phase 4,Phase 3,Phase 2
26 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
27 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2
30
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-74-1 65513
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antipruritics Phase 4,Phase 3,Phase 2
33 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Vaccines Phase 4,Phase 2
37 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
41 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Kininogens Phase 4,Phase 3,Phase 2,Phase 1
44 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Immunoglobulin E Phase 4
46 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
47 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
48 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 4,Phase 1

Interventional clinical trials:

(show top 50) (show all 315)

id Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria Unknown status NCT00346606 Phase 4 Denosin® and Xyzal®
2 Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses Completed NCT01250652 Phase 4 Levocetirizine;Levocetirizine plus Hydroxyzine
3 Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
4 Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria Completed NCT01444196 Phase 4 Desloratadine
5 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4 Cetirizine;Desloratadine;Fexofenadine;Ebastine;Bilastine
6 A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions Completed NCT00600847 Phase 4 desloratadine;desloratadine;placebo
7 CUTE (Chronic Urticaria Treatment Evaluation) Completed NCT00264303 Phase 4 Levocetirizine;Desloratadine
8 Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) Completed NCT00536380 Phase 4 5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine
9 A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
10 A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) Completed NCT00783354 Phase 4 desloratadine;desloratadine
11 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540) Completed NCT00795522 Phase 4 Desloratadine
12 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Completed NCT00751218 Phase 4 desloratadine;placebo;cetirizine
13 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed NCT02576041 Phase 4 Bilastine;Placebo
14 A Post Marking Study to Evaluate the Safety of FluMist in Children Completed NCT00569894 Phase 4
15 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
16 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Completed NCT01121458 Phase 4 Clevidipine
17 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
18 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
19 Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR Completed NCT01880840 Phase 4 205.5 mcg of azelastine hydrochloride;137 mcg of azelastine hydrochloride
20 A Call Center During HAE Attacks (SOS HAE) Completed NCT01679912 Phase 4
21 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Completed NCT01467947 Phase 4
22 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE Completed NCT01457430 Phase 4 Icatibant
23 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE Completed NCT00914966 Phase 4
24 Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Recruiting NCT02742805 Phase 4 Omalizumab
25 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU) Recruiting NCT03111628 Phase 4 Omalizumab
26 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Recruiting NCT02550080 Phase 4 Dapsone
27 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy Recruiting NCT02966314 Phase 4 Omalizumab;Placebos
28 Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria Active, not recruiting NCT01701583 Phase 4 Omalizumab
29 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody Not yet recruiting NCT03183024 Phase 4
30 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
31 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736) Terminated NCT00751166 Phase 4 Desloratadine;Cetirizine;placebo
32 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema Terminated NCT01574248 Phase 4 icatibant
33 C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
34 Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Unknown status NCT02166151 Phase 3 Omalizimab
35 Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Unknown status NCT02372604 Phase 3 Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
36 Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Completed NCT00598611 Phase 3 desloratadine;desloratadine
37 Bilastine Updosing in Chronic Spontaneous Urticaria Completed NCT02213367 Phase 3 Bilastine;Bilastine;Bilastin
38 Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3 placebo;prednisone
39 Methotrexate in the Treatment of Chronic Idiopathic Urticaria Completed NCT01960283 Phase 3 Methotrexate (Novatrex ®) + anti-H1;Placebo + anti-H1
40 Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria Completed NCT01715740 Phase 3 Chinese Herbal Medicine (CHM);Placebo
41 Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria Completed NCT00421109 Phase 3 Bilastine;Levocetirizine;Placebo
42 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients Completed NCT02161562 Phase 3 omalizumab;omalizumab
43 An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) Completed NCT01916967 Phase 3 Desloratadine;Placebo
44 How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988) Completed NCT00795158 Phase 3 desloratadine
45 Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Completed NCT01803763 Phase 2, Phase 3 Omalizumab (Xolair);Placebo
46 Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria Completed NCT00525382 Phase 3 levocetirizine dihydrochloride
47 A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed NCT01264939 Phase 3 Omalizumab;Placebo;H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;Diphenhydramine
48 Bilastine Updosing - Characterization of Underlying Mechanisms Completed NCT01271075 Phase 2, Phase 3 Bilastine;Bilastine
49 Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction. Completed NCT02023164 Phase 3 JDP-205 Injection;Diphenhydramine
50 Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Completed NCT00619801 Phase 3 Levocetirizine;Placebo

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Urticaria

Genetic tests related to Urticaria:

id Genetic test Affiliating Genes
1 Urticaria 29

Anatomical Context for Urticaria

MalaCards organs/tissues related to Urticaria:

39
Skin, Testes, Thyroid, Bone, T Cells, Brain, Neutrophil

Publications for Urticaria

Articles related to Urticaria:

(show top 50) (show all 1711)
id Title Authors Year
1
Longitudinal Study of Pediatric Urticaria Pigmentosa. ( 28133781 )
2017
2
Case of cholinergic urticaria accompanied by anaphylaxis. ( 28665007 )
2017
3
Solar urticaria with an augmentation spectrum in a child. ( 28543282 )
2017
4
Allergic contact urticaria secondary to hair dye use. ( 28872198 )
2017
5
Angioedema without urticaria caused by oral acitretin. ( 28941265 )
2017
6
Early-onset urticaria: a marker of cryopyrin-associated periodic syndrome. ( 28512856 )
2017
7
Chronic Urticaria and Irritable Bowel Syndrome: a Cross-Sectional Study of 11,271 Patients. ( 28906546 )
2017
8
Refractory solar urticaria successfully treated with omalizumab with normalization of phototest. ( 28168968 )
2017
9
Urticaria Pigmentosa Mimicking Multiple Lentigine-like Brownish Macules in a 22-Month-Old Boy. ( 28480643 )
2017
10
Investigation of thiol-disulphide balance in patients with acute urticaria and chronic spontaneous urticaria. ( 27927024 )
2017
11
The Histopathology of Urticaria Revisited-Clinical Pathological Study. ( 28858880 )
2017
12
Solar urticaria developing in patients with Erythropoietic Protoporphyria: a clue to the pathogenesis of Solar Urticaria? ( 28796891 )
2017
13
Benefit from Reslizumab Treatment in a Patient with Chronic Spontaneous Urticaria and Cold Urticaria. ( 28924988 )
2017
14
Cholinergic urticaria: Clinicoepidemiological paradigms from a tertiary care center in North India. ( 28731013 )
2017
15
Palmoplantar aquagenic urticaria: A case report. ( 28731018 )
2017
16
Physical urticaria. ( 28433981 )
2017
17
Recurrence of Chronic Urticaria: Incidence and Associated Factors. ( 28888844 )
2017
18
Seroprevalence of Toxocariasis In Children With Urticaria: A Population-Based Study. ( 28077610 )
2017
19
Inducible T-cell costimulator (ICOS) and CD28 polymorphisms possibly play a role in the pathogenesis of chronic autoreactive urticaria. ( 28940644 )
2017
20
Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management. ( 28382552 )
2017
21
Looking forward to new targeted treatments for chronic spontaneous urticaria. ( 28078079 )
2017
22
Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. ( 28870460 )
2017
23
Response to Omalizumab in Solar Urticaria: Report of 3 Cases. ( 28457471 )
2017
24
Yellow urticaria following plasma transfusion. ( 28894877 )
2017
25
Burden of chronic urticaria relative to psoriasis in five European countries. ( 28898460 )
2017
26
Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. ( 28389393 )
2017
27
Cholinergic urticaria patients of different age groups have distinct features. ( 28873238 )
2017
28
Beyond Urticaria: Schnitzler Syndrome. ( 28552842 )
2017
29
Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study. ( 28884989 )
2017
30
Solar urticaria with a wide action spectrum from UVB to visible light complicated with UVA-induced polymorphous light eruption. ( 28160768 )
2017
31
Synergistic Actions of Histamine-Releasing Factor and Histamine Releasing Factor-Reactive IgE in Chronic Urticaria. ( 28219065 )
2017
32
Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria. ( 28583263 )
2017
33
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria. ( 28685545 )
2017
34
Urticaria pigmentosa with concomitant polycythaemia vera in a 3-year-old boy. ( 28614617 )
2017
35
Atopic Dermatitis and Allergic Urticaria: Cutaneous Manifestations of Immunodeficiency. ( 27886899 )
2017
36
When should the diagnosis 'contact urticaria' be used? ( 28940487 )
2017
37
Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic Review. ( 28916431 )
2017
38
Immunological Mechanisms Implicated in the Pathogenesis of Chronic Urticaria and Hashimoto Thyroiditis. ( 28865416 )
2017
39
The link between chronic spontaneous urticaria and metabolic syndrome. ( 28884987 )
2017
40
Angioedema, Stomatitis, and Urticaria Caused by Contact Allergy to Invisalign. ( 28885312 )
2017
41
Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases. ( 27876252 )
2017
42
A case of cholinergic urticaria with localized hypohidrosis showing sweat gland eosinophilic infiltration. ( 28108244 )
2017
43
Aquagenic Urticaria Diagnosed by the Water Provocation Test and the Results of Histopathologic Examination. ( 28566914 )
2017
44
Contact urticaria caused by the ultraviolet absorber octocrylene in sunscreens. ( 28872203 )
2017
45
Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations. ( 28913986 )
2017
46
Contact Urticaria to Nickel: A Series of 11 Patients Who Were Prick Test Positive and Patch Test Negative to Nickel Sulfate 2.5% and 5.0. ( 27649351 )
2016
47
Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria. ( 27639259 )
2016
48
Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. ( 27496595 )
2016
49
Cold urticaria: a 20-year follow-up study. ( 27422852 )
2016
50
Altered expression of chemoattractant receptor-homologous molecule expressed on T(H)2 cells on blood basophils and eosinophils in patients with chronic spontaneous urticaria. ( 26194547 )
2016

Variations for Urticaria

ClinVar genetic disease variations for Urticaria:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232

Expression for Urticaria

Search GEO for disease gene expression data for Urticaria.

Pathways for Urticaria

GO Terms for Urticaria

Cellular components related to Urticaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AOC1 C1S CMA1 CPN1 F12 FCER2
2 extracellular exosome GO:0070062 9.32 AOC1 C1S F12 FCER2 HNMT PLCG2

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.71 C1S F12 NLRP3 SERPING1
2 regulation of complement activation GO:0030449 9.67 C1S CPN1 SERPING1
3 positive regulation of receptor internalization GO:0002092 9.55 PLCG2 SELE
4 prostaglandin metabolic process GO:0006693 9.54 PTGS1 PTGS2
5 fibrinolysis GO:0042730 9.52 F12 SERPING1
6 blood coagulation, intrinsic pathway GO:0007597 9.51 F12 SERPING1
7 cellular oxidant detoxification GO:0098869 9.5 LTC4S PTGS1 PTGS2
8 lipoxygenase pathway GO:0019372 9.48 LTC4S PTGS2
9 prostaglandin biosynthetic process GO:0001516 9.46 PTGS1 PTGS2
10 leukotriene biosynthetic process GO:0019370 9.43 FCER1A LTC4S
11 response to glucocorticoid GO:0051384 9.43 CPN1 HNMT PTGS2
12 inflammatory response GO:0006954 9.43 ADGRE2 HRH1 NLRP3 PTGS1 PTGS2 SELE
13 cyclooxygenase pathway GO:0019371 9.37 PTGS1 PTGS2
14 regulation of blood coagulation GO:0030193 9.26 F12
15 cellular response to histamine GO:0071420 9.16 AOC1 HRH1
16 regulation of inflammatory response GO:0050727 8.92 CMA1 NLRP3 PTGS2 SELE

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 IgE binding GO:0019863 8.96 FCER1A FCER2
2 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Urticaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....